Relieves symptoms of depression. ANDA 91099, held by Hikma. Imipramine Pamoate.
As of Nov 16, 2026, ANDA 91099 (Imipramine Pamoate), held by Hikma, was first approved by FDA on Apr 16, 2010, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 16, 2010 | Original application | Approved | None posted |
| Imipramine PamoateEQ 75MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Rx |
| Imipramine PamoateEQ 100MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Rx |
| Imipramine PamoateEQ 125MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Rx |
| Imipramine PamoateEQ 150MG HYDROCHLORIDE · capsule;oral | Imipramine Pamoate | Rx |
| Jun 24, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 2, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 21, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 16, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters